Gene editing expert Charlie Albright tells us why he hopped from Editas to a new role as CSO of an upstart biotech out to engineer gene therapy 2.0

We now know where Charlie Albright was headed when he jumped ship at CRISPR gene editing pioneer Editas a few weeks ago.

Albright has …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gene edit­ing ex­pert Char­lie Al­bright tells us why he hopped from Ed­i­tas to a new role as CSO of an up­start biotech out to en­gi­neer gene ther­a­py 2.0